Stock Analysis on Net

Elevance Health Inc. (NYSE:ELV)

Cash Flow Statement
Quarterly Data

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Elevance Health Inc., consolidated cash flow statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net income 831 1,300 1,856 2,004 961 1,613 1,650 1,795 1,125 1,502 1,801 1,667 551 222 2,276 1,523 934 1,183 1,139 1,551
Net (gains) losses on financial instruments 336 124 121 113 111 57 231 151 (211) 61 (172) 4 59 (247) (75) 81 (7) 12 (4) (68)
Equity in net (earnings) losses of other invested assets (37) (3) 43 30 11 (46) (105) (153) (125) (128) (201) (108)
Depreciation and amortization 424 426 433 462 473 451 393 358 360 351 309 282 290 308 286 270 246 301 297 289
Impairment of property and equipment 446 7 73 3 195
Deferred income taxes (241) 32 (138) (255) 94 2 (80) (92) 212 122 (39) 31 (438) (162) 3 57 110 (108) 24 55
Share-based compensation 72 78 78 61 73 69 72 50 59 63 69 64 69 80 67 67 68 86 70 70
Receivables, net (1,035) (428) (270) (29) (1,832) (16) 686 (1,348) (387) (119) (374) (1,258) 589 (532) 326 (639) (173) (291) 164 (753)
Other invested assets (33) (4) (27) (15) (35) 14 25 7 (14) (12) (24) (20) (38) (18) (39) 63 (18) (2) (7) (21)
Other assets 261 (407) (181) (348) 594 (55) (66) (353) 507 (223) 41 (288) 705 (502) 39 (525) 110 (22) (133) (125)
Policy liabilities (186) (250) 277 306 717 23 439 1,075 269 416 457 1,455 1,904 600 332 692 432 143 460 791
Unearned income (2,930) (126) 64 3,282 (2,590) 2,730 (239) 57 195 (128) (61) (119) 297 15 (1) (109) 69 48 (98) 96
Accounts payable and other liabilities (77) 1,557 142 18 226 (34) 204 428 (374) 533 202 358 25 85 1,280 588 (189) 127 (29) (354)
Income taxes (360) (134) (448) 839 (297) 118 (727) 568 (28) 62 (332) 438 (32) (1,209) 822 491 (244) 205 (401) 115
Other, net 4 2 1 (31) (2) (31) (2) 11 4 7 (1) (171) 15 194 (44) (11) (15) (45) (16)
Changes in operating assets and liabilities (4,356) 210 (443) 4,054 (3,248) 2,778 291 432 179 533 (84) 565 3,279 (1,546) 2,953 517 (24) 193 (89) (267)
Adjustments to reconcile net income to net cash provided by operating activities (3,802) 1,313 94 4,465 (2,479) 3,311 802 746 547 1,002 (118) 838 3,262 (1,372) 3,234 992 393 484 298 79
Net cash provided by operating activities (2,971) 2,613 1,950 6,469 (1,518) 4,924 2,452 2,541 1,672 2,504 1,683 2,505 3,813 (1,150) 5,510 2,515 1,327 1,667 1,437 1,630
Purchases of investments 8,101 (6,689) (10,205) (7,443) (5,334) (6,359) (8,203) (5,050) (3,539) (3,909) (4,243) (6,978) (2,784) (5,573) (7,239) (3,896) (5,644) (6,197) (5,044) (6,069)
Proceeds from sale of investments 2,766 2,491 2,850 2,489 2,586 2,262 4,093 3,047 1,930 1,994 1,695 4,650 2,579 4,015 1,996 2,728 5,766 3,997 3,599 5,236
Maturities, calls and redemptions from investments (11,591) 3,875 7,123 3,533 3,014 3,259 3,138 1,209 956 1,142 1,248 998 978 1,927 1,239 597 854 689 501 393
Changes in securities lending collateral 23 (90) (59) 204 376 (57) (179) (441) 74 (388) 89 (731) (181) 96 (687) (77) 115 99 26 14
Purchases of subsidiaries, net of cash acquired 18 81 (13) (1,638) (26) (14) (548) (61) (34) (3,415) (27) (3) (67) 2 (1,908)
Purchases of property and equipment (326) (319) (350) (301) (298) (305) (295) (254) (340) (258) (285) (204) (278) (306) (233) (204) (351) (271) (221) (234)
Other, net (20) (36) (18) (28) (29) (33) (30) (28) (13) (21) (14) (15) (6) (3) (12) (24) (17) (15) (26) 8
Net cash used in investing activities (1,029) (687) (672) (3,184) 289 (1,247) (2,024) (1,578) (966) (1,440) (4,925) (2,307) 305 89 (4,934) (2,784) 723 (1,698) (1,165) (652)
Net proceeds from (repayments of) commercial paper borrowings (90) (235) 325 (675) 125 25 225 200 (450) 550 (250) 250 (1,305) 905 (100) (400) 25 178
Proceeds from long-term borrowings 2,574 1,785 (14) 1,300 3,462 (1) 1 2,184 300 2,473 (2) 2
Repayments of long-term borrowings (1) (1,908) (917) (39) (929) (14) (114) (2) (952) (968) (809) (103) (52) (200) (850) (10) (63)
Proceeds from short-term borrowings 225 90 1,275 1,150 175 150 (255) 1,075 1,110 1,675 2,095 2,710
Repayments of short-term borrowings (175) (90) (1,375) (1,050) (150) (820) (700) (1,120) (1,975) (2,180) (2,760)
Changes in securities lending payable (23) 91 60 (205) (383) 65 179 441 (74) 388 (89) 731 181 (96) 687 77 (115) (99) (26) (14)
Changes in bank overdrafts 637 (23) (209) (291) 752 (636) 288 529 (692) (48) 364
Repurchase and retirement of common stock (928) (480) (646) (622) (568) (579) (624) (545) (522) (451) (480) (447) (1,358) (758) (55) (529) (305) (644) (458) (294)
Cash dividends (346) (348) (350) (351) (305) (306) (309) (309) (273) (276) (278) (277) (234) (238) (242) (240) (202) (204) (206) (206)
Proceeds from issuance of common stock under employee stock plans 40 31 38 43 30 36 40 76 42 20 52 89 64 20 48 44 50 37 24 76
Taxes paid through withholding of common stock under employee stock plans (1) (98) (2) (3) (2) (86) (1) (8) (2) (91) (16) (1) (4) (107) (2) (2) (2) (78)
Other, net 2 3 2 25 6 5 5 19 (3) (160) 171 (135) 747 (30) (94) (420) 133 63 20
Net cash provided by (used in) financing activities (394) (994) (1,430) (531) (258) (1,255) (127) 322 (1,315) (830) (820) 3,388 (2,367) (984) 105 679 (1,304) 144 (677) (429)
Effect of foreign exchange rates on cash and cash equivalents 1 (4) 1 1 2 (6) (6) (4) (1) (2) (6) (1) 6 1 2 (2) 1 (1) 1 (1)
Change in cash and cash equivalents (4,393) 928 (151) 2,755 (1,485) 2,416 295 1,281 (610) 232 (4,068) 3,585 1,757 (2,044) 683 408 747 112 (404) 548

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Elevance Health Inc. net cash provided by operating activities increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023.
Net cash used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Elevance Health Inc. net cash used in investing activities decreased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Elevance Health Inc. net cash provided by (used in) financing activities increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.